FUSN · Fusion Pharmaceuticals
Acquired Company
AstraZeneca acquired Fusion Pharmaceuticals on 6/4/2024 for US$21.00 per share in cash at closing plus a non-transferable contingent value right of US$3.00 per share in cash, representing a transaction value of approximately US$2.4 billion.
On June 6, 2024, AstraZeneca announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc. Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. The Company is advancing a pipeline of targeted radiopharmaceutical cancer therapies for a broad array of tumor types based upon its proprietary platform technology.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$21.55
Open
$21.55
Volume
N/A
Day Range
$21.55 - $21.55
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
0.47%
Institutional Own.
86.80%
Qtr Updated
Jun 30th 2024